Evidence map›Paper›PMID 24190578›Full record

Trial reportJAMA internal medicine2014

Gabapentin treatment for alcohol dependence: a randomized clinical trial.

Barbara J Mason, Susan Quello, Vivian Goodell, Farhad Shadan, Mark Kyle, Adnan Begovic

4 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JAMA internal medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 161 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
161citing papers in PubMed, 5 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00391716 phase2completednot on this map

Gabapentin Treatment of Alcohol Dependence

TypeinterventionalSponsorThe Scripps Research InstituteRan2004 to 2010Enrolled150ConditionsAlcoholism, Alcohol DependenceArmsGabapentin 900mg, behavioral counseling, placebo, gabapentin 1800mg
NCT02771925 phase4terminatednot on this mapstarted 2016, after this paper: background citation

Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial

TypeinterventionalSponsorDayanand Medical College and HospitalRan2016 to 2018Enrolled25ConditionsAlcohol DependenceArmsGabapentin 2g/day divided in two doses for 24 weeks, Placebo 2g/day divided in two doses for 24 weeks
NCT03220776 phase2completednot on this mapstarted 2017, after this paper: background citation

Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics

TypeinterventionalSponsorMedical University of South CarolinaRan2017 to 2022Enrolled54ConditionsAlcohol Use Disorder, Bipolar DisorderArmsN-Acetylcysteine, Gabapentin, Placebo Oral Tablet
NCT03334903 phase4completednot on this mapstarted 2018, after this paper: background citation

Gabapentin Regimens and Their Effects on Opioid Consumption

TypeinterventionalSponsorBrigham and Women's HospitalRan2018 to 2019Enrolled77ConditionsKnee Osteoarthritis, Knee Pain Chronic, Opioid Use, Opioid DependenceArmsGabapentin
3 · Its place in the literature

Who cites it

161 citing papers in PubMed, 5 syntheses or guidelines pooled it, 334 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

101 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Barbara J MasonThe Scripps Research Institute, Pearson Center for Alcoholism and Addiction Research, La Jolla, California.
Susan QuelloThe Scripps Research Institute, Pearson Center for Alcoholism and Addiction Research, La Jolla, California.
Vivian GoodellThe Scripps Research Institute, Pearson Center for Alcoholism and Addiction Research, La Jolla, California.
Farhad ShadanScripps Clinic and Scripps Green Hospital, La Jolla, California.
Mark KyleScripps Clinic and Scripps Green Hospital, La Jolla, California.
Adnan BegovicScripps Clinic and Scripps Green Hospital, La Jolla, California.
Pearson (United States) · USScripps Clinic · USScripps Green Hospital · US

Funding

Gabapentin Treatment of Alcohol DependenceR37AA014028 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI MASON, BARBARA J · 2003 to 2012
$6.1M
NIAAA NIH HHS R01 AA014028NIAAA NIH HHS R37 AA014028NIAAA NIH HHS R37AA014028
6 · The paper itself

Abstract

importanceApproved medications for alcohol dependence are prescribed for less than 9% of US alcoholics.

objectiveTo determine if gabapentin, a widely prescribed generic calcium channel/γ-aminobutyric acid-modulating medication, increases rates of sustained abstinence and no heavy drinking and decreases alcohol-related insomnia, dysphoria, and craving, in a dose-dependent manner. DESIGN, PARTICIPANTS AND

settingA 12-week, double-blind, placebo-controlled, randomized dose-ranging trial of 150 men and women older than 18 years with current alcohol dependence, conducted from 2004 through 2010 at a single-site, outpatient clinical research facility adjoining a general medical hospital.

interventionsOral gabapentin (dosages of 0 [placebo], 900 mg, or 1800 mg/d) and concomitant manual-guided counseling. MAIN OUTCOMES AND MEASURES: Rates of complete abstinence and no heavy drinking (coprimary) and changes in mood, sleep, and craving (secondary) over the 12-week study. RESULTS Gabapentin significantly improved the rates of abstinence and no heavy drinking. The abstinence rate was 4.1% (95% CI, 1.1%-13.7%) in the placebo group, 11.1% (95% CI, 5.2%-22.2%) in the 900-mg group, and 17.0% (95% CI, 8.9%-30.1%) in the 1800-mg group (P = .04 for linear dose effect; number needed to treat [NNT] = 8 for 1800 mg). The no heavy drinking rate was 22.5% (95% CI, 13.6%-37.2%) in the placebo group, 29.6% (95% CI, 19.1%-42.8%) in the 900-mg group, and 44.7% (95% CI, 31.4%-58.8%) in the 1800-mg group (P = .02 for linear dose effect; NNT = 5 for 1800 mg). Similar linear dose effects were obtained with measures of mood (F2 = 7.37; P = .001), sleep (F2 = 136; P < .001), and craving (F2 = 3.56; P = .03). There were no serious drug-related adverse events, and terminations owing to adverse events (9 of 150 participants), time in the study (mean [SD], 9.1 [3.8] weeks), and rate of study completion (85 of 150 participants) did not differ among groups. CONCLUSIONS AND RELEVANCE: Gabapentin (particularly the 1800-mg dosage) was effective in treating alcohol dependence and relapse-related symptoms of insomnia, dysphoria, and craving, with a favorable safety profile. Increased implementation of pharmacological treatment of alcohol dependence in primary care may be a major benefit of gabapentin as a treatment option for alcohol dependence.

trial registrationclinicaltrials.gov Identifier: NCT00391716.

Indexed as

AdultAlcohol AbstinenceAlcoholismAminesCentral Nervous System DepressantsCyclohexanecarboxylic AcidsDouble-Blind MethodEthanolFemaleGABA ModulatorsGabapentingamma-Aminobutyric AcidHumansMaleMiddle AgedSubstance Withdrawal SyndromeAminesCentral Nervous System DepressantsCyclohexanecarboxylic AcidsEthanolGABA ModulatorsGabapentingamma-Aminobutyric Acid

Identifiers

PMID24190578
PMCPMC3920987
OpenAlexW2159492208

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.